Preclinical studies using both in vitro and in vivo model systems and Phase I clinical trials have shown that treatment with anti-IGF-1R antibodies can inhibit several steps in breast cancer progression, including proliferation, survival, motility, invasion, and metastasis [146,147,148,149,150]. This evidence concerns the gene IGF1R and breast cancer.